James F Oliviero Iii Checkpoint Therapeutics, Inc. (CKPT) insider trading activity

James F Oliviero Iii is CEO, President and Director of Checkpoint Therapeutics, Inc.. Currently has a direct ownership of 2.29 Million shares of CKPT, which is worth approximately $8.6 Million. The most recent transaction as insider was on Dec 20, 2024, when has been sold 900,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.29M

18.32% 3M change

482.25% 12M change

Total Value Held $8.6 Million

James F Oliviero III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 20 2024	SELL Bona fide gift	-	900,000 Reduced 28.17%	2,294,583 Common Stock
Dec 19 2024	SELL Open market or private sale	$744,377 $3.38 p/Share	220,230 Reduced 6.45%	3,194,583 Common Stock
Dec 18 2024	SELL Open market or private sale	$2,330,386 $3.87 p/Share	602,167 Reduced 14.99%	3,414,813 Common Stock
Dec 13 2024	BUY Grant, award, or other acquisition	-	2,077,700 Added 34.09%	4,016,980 Common Stock
Jun 26 2024	SELL Bona fide gift	-	37,890 Reduced 1.92%	1,939,280 Common Stock
Jun 26 2024	SELL Open market or private sale	$50,450 $2.05 p/Share	24,610 Reduced 1.23%	1,977,170 Common Stock
May 24 2024	BUY Grant, award, or other acquisition	-	1,660,000 Added 45.33%	2,001,780 Common Stock (restricted)
Feb 28 2024	SELL Bona fide gift	-	9,056 Reduced 2.58%	341,780 Common Stock
Feb 28 2024	SELL Open market or private sale	$12,141 $2.06 p/Share	5,894 Reduced 1.65%	350,836 Common Stock
Feb 01 2024	SELL Open market or private sale	$23,918 $2.01 p/Share	11,900 Reduced 3.12%	369,680 Common Stock
Feb 01 2024	SELL Bona fide gift	-	12,950 Reduced 3.5%	356,730 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	250,000 Added 38.81%	394,090 Common Stock (restricted)
Mar 02 2023	SELL Open market or private sale	$27,415 $5.0 p/Share	5,483 Reduced 3.67%	144,090 Common Stock
Feb 27 2023	SELL Open market or private sale	$25,798 $4.65 p/Share	5,548 Reduced 3.96%	134,573 Common Stock
Feb 27 2023	BUY Grant, award, or other acquisition	-	15,000 Added 9.11%	149,573 Common Stock
Feb 01 2023	SELL Open market or private sale	$48,944 $4.77 p/Share	10,261 Reduced 5.33%	182,121 Common Stock
Jan 10 2023	SELL Open market or private sale	$25,764 $6.75 p/Share	3,817 Reduced 1.95%	192,382 Common Stock
Jun 23 2022	SELL Open market or private sale	$16,650 $1.11 p/Share	15,000 Reduced 0.58%	2,562,003 Common Stock
Jun 22 2022	SELL Open market or private sale	$13,080 $1.09 p/Share	12,000 Reduced 0.46%	2,577,003 Common Stock
Jun 21 2022	SELL Open market or private sale	$22,890 $1.09 p/Share	21,000 Reduced 0.8%	2,589,003 Common Stock
Jun 17 2022	SELL Open market or private sale	$248,520 $1.09 p/Share	228,000 Reduced 8.03%	2,610,003 Common Stock
Apr 13 2022	SELL Open market or private sale	$32,100 $1.51 p/Share	21,258 Reduced 0.74%	2,838,003 Common Stock
Apr 05 2022	SELL Open market or private sale	$24,833 $1.77 p/Share	14,030 Reduced 0.49%	2,859,261 Common Stock
Apr 04 2022	SELL Open market or private sale	$154,572 $1.79 p/Share	86,353 Reduced 2.92%	2,873,291 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$217,665 $1.85 p/Share	117,657 Reduced 3.82%	2,959,644 Common Stock

Also insider at

NVCT

Nuvectis Pharma, Inc. Healthcare

Director

JFO